Snowball logo
logo
FGEN_logo

FibroGen, Inc. ORD SHS

₽710.00₽0.00  (0%)
Forecast
EPS (FWD)
-11.95
About the company
Ticker
FGEN-RM
ISIN
US31572Q8087
Country
Other
Sector (GICS)
Healthcare
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Frequently asked questions

What sector does FibroGen, Inc. ORD SHS (FGEN-RM) operate in?

FibroGen, Inc. ORD SHS belongs to the Healthcare sector and operates in the Biotechnology industry.

What is FibroGen, Inc. ORD SHS (FGEN-RM) current stock price?

As of the latest data, FibroGen, Inc. ORD SHS stock price is RUB 710.00, with a previous close of RUB 710.00.

What is FibroGen, Inc. ORD SHS (FGEN-RM) current market capitalization?

FibroGen, Inc. ORD SHS market cap is approximately 39.28 million.

Does FibroGen, Inc. ORD SHS (FGEN-RM) pay dividends?

No. FibroGen, Inc. ORD SHS does not pay a dividend.

What is FibroGen, Inc. ORD SHS (FGEN-RM) beta (volatility) score?

FibroGen, Inc. ORD SHS has a beta of 0.000, indicating lower volatility than the overall market.